DECN: AI 评分 48/100 — AI 分析 (4月 2026)

Decision Diagnostics Corp. focuses on developing and distributing diagnostic products and electronic medical record (EMR) technologies. The company's primary offerings include glucose test strips and related systems for both human and animal use, along with EMR software solutions.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Decision Diagnostics Corp., operating in the medical pharmaceutical sector, develops and distributes diagnostic products, including glucose test strips and EMR technologies. Their focus on at-home testing and cell phone-centric e-health solutions positions them in a niche market, though they face challenges typical of OTC-listed companies with limited resources.

DECN是做什么的？

Founded in 2000 and based in Westlake Village, California, Decision Diagnostics Corp. (formerly InstaCare Corp.) is a developer, manufacturer, and distributor of diagnostic products and electronic medical record (EMR) technologies. The company's core business revolves around providing solutions for diabetes management, including its GenUltimate! line of glucose test strips designed for at-home use. These strips are Class II medical devices intended for self-monitoring of blood glucose levels. Additionally, Decision Diagnostics offers PetSure! glucose test strips for monitoring glucose in dogs and cats, compatible with legacy glucometers like the Zoetis AlphaTrak. Beyond glucose testing, Decision Diagnostics provides the GenUltimate! 4Pets Glucose system, a proprietary system for testing glucose levels in dogs, cats, and horses. The company also develops and licenses EMR technologies, including MD@Hand, an inpatient/outpatient management suite, Practice Probe, a data mining utility for physician practice management systems, and ResidenceWare, a residential management system. Decision Diagnostics also engages in acquiring and holding intellectual property, including patents, trademarks, and specialty manufacturing equipment, to support its product lines and technology offerings. The company distributes its products and services through a combination of direct sales, partnerships, and distribution agreements.

DECN的投资论点是什么？

Decision Diagnostics Corp. presents a speculative investment opportunity within the healthcare diagnostics market. The company's focus on glucose testing and EMR technologies caters to the growing demand for at-home diagnostics and digital health solutions. However, its OTC listing and limited financial resources pose significant risks. Key value drivers include potential revenue growth from its GenUltimate! line of glucose test strips and the adoption of its EMR technologies. The company's success hinges on securing regulatory approvals, expanding its distribution network, and managing its operating expenses. Investors should carefully consider the risks associated with investing in an OTC-listed company with a small market capitalization and negative profit margins. The company's beta of -0.04 indicates a low correlation with the overall market.

DECN在哪个行业运营？

The medical diagnostics industry is experiencing growth driven by increasing prevalence of chronic diseases like diabetes, advancements in technology, and a growing demand for point-of-care and at-home testing solutions. The market is competitive, with established players like Abbott and Roche dominating the space. Decision Diagnostics operates in a niche segment, focusing on glucose testing and EMR technologies. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and effectively compete with larger, more established companies. The global medical device market is projected to reach $600 billion by 2025, highlighting the potential for growth in this sector.

Medical - Pharmaceuticals

Healthcare

DECN有哪些增长机遇？

Expansion of GenUltimate! Product Line: The company can expand its GenUltimate! line of glucose test strips by introducing new products and features, such as continuous glucose monitoring (CGM) systems and integrated mobile apps. The global CGM market is projected to reach $10 billion by 2027, presenting a significant opportunity for Decision Diagnostics to capture market share.
Strategic Partnerships: Forming strategic partnerships with healthcare providers, pharmacies, and diabetes management programs can expand the company's distribution network and reach a wider customer base. Collaborating with telehealth companies can also integrate the company's EMR technologies into virtual care platforms, increasing adoption and revenue streams.
Geographic Expansion: Expanding into new geographic markets, particularly emerging economies with growing diabetes populations, can drive revenue growth. The company can target countries with limited access to healthcare services and a high prevalence of diabetes, offering affordable and accessible glucose testing solutions.
Development of New EMR Technologies: Investing in the development of new EMR technologies, such as AI-powered diagnostic tools and remote patient monitoring systems, can enhance the company's product portfolio and attract new customers. The global EMR market is projected to reach $40 billion by 2028, indicating a significant growth opportunity for Decision Diagnostics.
Acquisition of Complementary Businesses: Acquiring complementary businesses in the healthcare diagnostics or EMR space can expand the company's product offerings, customer base, and market share. The company can target companies with innovative technologies or established distribution networks, creating synergies and driving revenue growth.

Gross Margin of 25.2% indicates potential profitability in its product sales, but needs to be scaled.
Negative Profit Margin of -1499.1% reflects significant operational challenges and the need for improved cost management.
The company's focus on at-home glucose testing aligns with the growing trend of remote patient monitoring.
The development of cell phone-centric e-health products positions the company to capitalize on the increasing adoption of mobile health technologies.
The company's intellectual property portfolio, including patents and trademarks, provides a potential competitive advantage.

DECN提供哪些产品和服务？

Develops and manufactures glucose test strips for human and animal use.
Provides at-home testing products for individuals with chronic illnesses.
Offers fulfillment services for direct-to-patient diabetes programs.
Develops cell phone-centric e-health products and technologies.
Offers EMR technologies for physicians at the point of care.
Acquires and holds intellectual property, including patents and trademarks.

DECN如何赚钱？

Sales of GenUltimate! glucose test strips and related products.
Licensing of EMR technologies to healthcare providers.
Fulfillment services for diabetes management programs.
Acquisition and monetization of intellectual property.

Individuals with diabetes who require at-home glucose monitoring.
Veterinarians and pet owners who need to monitor glucose levels in animals.
Physicians and healthcare providers who use EMR technologies.
Diabetes management programs and telehealth companies.

Proprietary GenUltimate! glucose test strip technology.
Intellectual property portfolio, including patents and trademarks.
Established relationships with healthcare providers and distributors.
Focus on niche markets, such as glucose testing for animals.

什么因素可能推动DECN股价上涨？

Upcoming: Potential FDA approvals for new diagnostic products.
Ongoing: Expansion of distribution network through strategic partnerships.
Ongoing: Development and launch of new EMR technologies.
Ongoing: Increasing adoption of at-home glucose testing solutions.
Ongoing: Growth in the global diabetes market.

DECN的主要风险是什么？

Potential: Competition from larger, more established companies.
Potential: Regulatory hurdles and the need for FDA approvals.
Ongoing: Limited financial resources and negative profit margins.
Ongoing: OTC listing and lack of regulatory oversight.
Potential: Technological obsolescence and the emergence of new diagnostic technologies.

DECN的核心优势是什么？

Proprietary GenUltimate! glucose test strip technology.
Focus on niche markets, such as glucose testing for animals.
Development of cell phone-centric e-health products.
Intellectual property portfolio.

DECN的劣势是什么？

OTC listing and limited access to capital.
Negative profit margins and financial instability.
Small market capitalization and limited trading volume.
Dependence on a limited number of products and services.

DECN有哪些机遇？

Expansion of GenUltimate! product line.
Strategic partnerships with healthcare providers and telehealth companies.
Geographic expansion into emerging markets.
Development of new EMR technologies.

DECN面临哪些威胁？

Competition from larger, more established companies.
Regulatory hurdles and the need for FDA approvals.
Technological obsolescence and the emergence of new diagnostic technologies.
Economic downturns and reduced healthcare spending.

DECN的竞争对手是谁？

Ambisense Technologies Corp. — Focuses on environmental monitoring solutions. — (AMBS)
Axim Pharmaceuticals Inc. — Develops pharmaceutical products and cannabinoid-based therapies. — (AXMP)
IBX Group Inc. — Unknown business model. — (IBXG)
iTronics Corp. — Focuses on electronic components and solutions. — (ITMC)
Ligand Pharmaceuticals Inc. — Develops and acquires pharmaceutical assets. — (LGND)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Keith Berman
Headquarters: Westlake Village, US
Employees: 6
Founded: 2002

AI Insight

AI analysis pending for DECN

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Decision Diagnostics Corp. do?

Decision Diagnostics Corp. operates in the healthcare sector, focusing on the development, manufacture, and distribution of diagnostic products and electronic medical record (EMR) technologies. Their primary product is the GenUltimate! line of glucose test strips, designed for at-home use by individuals with diabetes. Additionally, they offer EMR software solutions for healthcare providers, aiming to improve patient care and streamline administrative processes. The company also caters to the veterinary market with glucose testing products for pets.

What do analysts say about DECN stock?

As of March 16, 2026, there is no readily available analyst coverage or consensus on Decision Diagnostics Corp. due to its OTC listing and small market capitalization. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, are either not applicable or unreliable due to the company's negative profit margins and limited trading volume. Investors should conduct their own independent research and consider the risks associated with investing in an OTC-listed company.

What are the main risks for DECN?

Decision Diagnostics Corp. faces several significant risks, including its OTC listing, which implies less stringent regulatory oversight and lower liquidity. The company's negative profit margins and limited financial resources raise concerns about its ability to sustain operations and fund future growth. Competition from larger, more established companies in the medical diagnostics and EMR markets poses a threat to its market share. Regulatory hurdles and the need for FDA approvals can delay or prevent the launch of new products.